Lithium Use During Pregnancy in 14 Countries
Year: 2024
Type: article
Study design: Observational Study
Abstract: Importance: In pregnancy, the benefits of lithium treatment for relapse prevention in psychiatric conditions must be weighed against potential teratogenic effects. Currently, there is a paucity of information on how and when lithium is used by pregnant women. Objective: To examine lithium use in the perinatal period. Design, Setting, and Participants: This cohort study used individual-level data of pregnancies from January 1, 2000, to December 31, 2021, in Australia, Denmark, Finland, Germany, Hong Kong, Iceland, Israel, New Zealand, Norway, South Korea, Sweden, Taiwan, the UK, and 2 cohorts in the US. Analyses were performed from September 1 to November 30, 2023. Exposures: The prevalence of lithium use as the proportion of pregnancies with at least 1 prescription fill or prescription within 3 months before pregnancy until childbirth was estimated using a common protocol. Lithium use during pregnancy by trimester and in the 3 months before and after pregnancy was examined. Main Outcomes and Measures: Comparison of prevalence between the first and last 3-year periods of available data. Results: Among 21 659 454 pregnancies from all collaborating sites, the prevalence of lithium use ranged from 0.07 per 1000 pregnancies in Hong Kong to 1.56 per 1000 in the US publicly insured population. Lithium use increased per 1000 pregnancies in 10 populations (Australia [0.60 to 0.74], Denmark [0.09 to 0.51], Finland [0.10 to 0.29], Iceland [0.24 to 0.99], Israel [0.25 to 0.37], Norway [0.24 to 0.47], South Korea [0.30 to 0.44], Sweden [0.42 to 1.07], the UK [0.07 to 0.10], and Taiwan [0.15 to 0.19]), remained stable in 4 populations (Germany [0.17 to 0.16], Hong Kong [0.06 to 0.06], and the publicly [1.50 to 1.34] and commercially [0.38 to 0.36] insured US populations), and decreased in 1 population (New Zealand [0.54 to 0.39]). Use of lithium decreased with each trimester of pregnancy, while prevalence of postpartum use was similar to prepregnancy levels. The proportion of lithium use in the second trimester compared with the prepregnancy period ranged from 2% in South Korea to 80% in Denmark. Conclusions and Relevance: Prevalence of lithium use in pregnant women over the past 2 decades varied markedly between populations. Patterns of use before, during, and after pregnancy suggest that many women discontinued lithium use during pregnancy and reinitiated treatment after childbirth, with large variations between countries. These findings underscore the need for internationally harmonized guidelines, specifically for psychiatric conditions among pregnant women that may benefit from lithium treatment.
Source: JAMA Network Open
Authors: Felix Wittström, Carolyn E. Cesta, Brian T. Bateman, Marie Bendix, Mette Bliddal, Adrienne Y. L. Chan, Yongtai Cho, Eun-Young Choi, Jacqueline M. Cohen, Sarah Donald, Mika Gissler, Alys Havard, Sonia Hernandez-Diaz, Krista F. Huybrechts, Bianca Kollhorst, Edward Chia-Cheng Lai, Maarit K. Leinonen, Brian M. H. Li, Kenneth K. C. Man, Vanessa W. S. Ng, Lianne Parkin, Laura Pazzagli, Lotte Rasmussen, Ran S. Rotem, Tania Schink, Ju-Young Shin, Duong T. Tran, Ian C. K. Wong, Helga Zoega, Johan Reutfors
Institutions: Karolinska Institutet, Stanford Medicine, Stanford University, Region Stockholm, Stockholm Health Care Services, Umeå University, University of Southern Denmark, Aston University, University of Hong Kong, Sungkyunkwan University, Norwegian Institute of Public Health, University of Otago, Finnish Institute for Health and Welfare, UNSW Sydney, National Drug and Alcohol Research Centre, Harvard University, Brigham and Women's Hospital, Leibniz Institute for Prevention Research and Epidemiology - BIPS, National Cheng Kung University, University of Helsinki, Helsinki University Hospital, National Health Service, University College London Hospitals NHS Foundation Trust, Laboratory of Data Discovery for Health, UCL School of Pharmacy, University College London, Maccabi Healthcare Services, Macau University of Science and Technology, University of Iceland
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Funders: University of Otago, Australian Government, University of New South Wales, Innovation and Technology Commission, Department of Health and Aged Care, Australian Government, Vetenskapsrådet, National Health Research Institutes, Forskningsrådet om Hälsa, Arbetsliv och Välfärd, NSW Ministry of Health, DAK-Gesundheit, Health and Welfare Data Science Center, National Science and Technology Council, National Health and Medical Research Council, National Drug and Alcohol Research Centre
Awards: Are nicotine replacement therapy and varenicline safe and effective for women trying to quit smoking during pregnancy?, Centre of Research Excellence in Medicines Intelligence, Polypharmacy and Discontinuation of Medication during Pregnancy in Women with Bipolar Disorder: Implications for Maternal Health
OpenAlex ID: W4405425839
